| Authors: |
Chevalier A; Cell Therapy and Tissue Bank Unit, Bordeaux, France., Bonneau B; Department of Medical Pharmacology, CIC1436, Toulouse University Hospital, Toulouse, France., Grote-Levi L; Department of Neurology, Hannover Medical School, Hannover, Germany., Möhn N; Department of Neuroimmunology, Department of Neurooncology, Center for Neurology, University Hospital Bonn, Bonn, Germany., Cinque P; Unit of Infectious Diseases and Unit of Neurovirology, IRCCS San Raffaele Scientific Institute, Milano, Italy., Rubinstein JD; Department of Pediatrics, University of Cincinnati College of Medicine, Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati., Wicklein R; Department of Neurology, TUM University Hospital, TUM School of Medicine, Technical University of Munich, Munich, Germany., Pfeiffer T; Department of Pediatrics, Division of Hematology/Oncology, Washington University School of Medicine, St. Louis, Missouri., Omer B; Texas Children's Cancer Center & Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas., Steinhardt M; Medizinische Klinik und Poliklinik II, University Hospital Würzburg, Germany., Tudesq JJ; Hematology Department, Montpellier University Hospital, Univ Montpellier, Montpellier, France., Testard N; Department of neurology, Vendée Hospital, La Roche-sur-Yon, France., Chevallier P; Department of Hematology, Nantes University Hospital, Nantes, France., Bernard-Valnet R; Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Switzerland., Maréchal ML; Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, GIN, Grenoble, France., Catalano G; Unit of Infectious Diseases and Unit of Neurovirology, IRCCS San Raffaele Scientific Institute, Milano, Italy., Pignolet B; Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, Université de Toulouse; Neo-I3D research group, Toulouse University Hospital, Toulouse, France., Sommet A; Department of Medical Pharmacology, CIC1436, Toulouse University Hospital, Toulouse, France., Eiz-Vesper B; Hannover Medical School (MHH), Institute of Transfusion Medicine and Transplant Engineering, Hannover, Germany; German Center for Infection Research (DZIF), Thematical Translation Unit-Immunocompromised Host (TTU-IICH), partner site Hannover-Braunschweig, Germany., Comoli P; Cell Factory and Center for Advanced Therapies, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Skripuletz T; Department of Neurology, Hannover Medical School, Hannover, Germany., Cortese I; Experimental Immunotherapeutics Unit, National Institute of Neurological Disorders and Stroke, Bethesda., Bensoussan D; Cell Therapy Unit Nancy, University Hospital Vandoeuvre-les-Nancy, France; CNRS Unit UMR 7365 IMoPA Lorraine University Vandoeuvre-les-Nancy, France., Martin-Blondel G; Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, Université de Toulouse; Neo-I3D research group, Toulouse University Hospital, Toulouse, France; Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, France. Electronic address: martin-blondel.g@chu-toulouse.fr. |
